Change language

02.04.26

N-of-1 therapies: personalised treatments for single patients

How N-of-1 therapies and antisense oligonucleotides enable personalised treatments for ultra-rare genetic diseases, from mutation to clinical use.

From Research

31.03.26

In memory of Claudio Bordignon, pioneer of gene therapy

His work combined scientific vision, experimental rigor and a constant focus on the potential impact of research for patients affected by severe inherited diseases.

From Telethon Foundation

23.03.26

Cytiva and San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) launch collaboration to advance next-generation genomic medicine platforms

New “Danaher Beacon,” first on the European continent, aims to accelerate translation, scalability, and reliability across cell and gene therapy workflows. Focus is on lentiviral gene transfer and targeted gene editing of hematopoietic stem cells.

From Telethon Foundation

12.03.26

Reaching the CNS with lentiviral gene therapy

SR-TIGET ex vivo and in vivo lentiviral gene therapy aims to target the CNS, building on MLD success and expanding toward new therapeutic strategies.

From Research

09.03.26

Tigem: technological platforms serving research

TIGEM’s core facilities combine advanced technology and scientific mentoring, accelerating growth and research for PhD students and postdocs.

From Research

02.03.26

Retinal dystrophies: gene-agnostic therapy based on miRNAs

New miR-based gene-agnostic strategies target shared mechanisms in retinal dystrophies, opening new therapeutic options beyond single-gene therapy. 

From Research

27.02.26

Fondazione Telethon announces positive CHMP opinion recommending unlimited renewal of Strimvelis™ marketing authorisation, ten years after first approval

The ADA-SCID gene therapy, manufactured and distributed by Fondazione Telethon in the European Union since 2023, continues to demonstrate a favourable benefit-risk balance.

From Telethon Foundation

23.02.26

AAV gene therapy for large genes: two TIGEM platforms

How AAV gene therapy for large genes overcomes size limits through two TIGEM technology platforms for inherited retinal and rare diseases.

From Research

11.02.26

February 11: The Value of Women in Research

Bioinformatics and translational research at TIGEM, as told by two of its leading women researchers, on the International Day of Women and Girls in Science. 

From Research

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.